Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.

A probiotic composition comprised of a probiotic, a prebiotic, a complex-starch reducing enzyme, an enzymatic co-factor, and a pH modifier. The probiotic composition facilitates the creation of a biofilm within the GI tract of poultry that outcompetes and excludes pathogens. The probiotic composition can be incorporated into an eggwash and sprayed onto an egg, the sprayed egg developing a stable probiotic population within the GI tract of the pre-hatched chick. The probiotic composition can also be incorporated into poultry feed by applying the probiotic composition as a mash prior to pelleting. The probiotic composition can also be applied post-pelleting as a wet or dry spray, directly onto the pellets. In some instances, the probiotic composition can be added a drinking water source used by poultry as a water additive. Poultry that consume feed or water that contain the probiotic composition develop a stable probiotic population within their GI tracts.

Novel Bifidobacterium bacteria having an opioid peptide decomposition action and a noncollagenous glycoprotein decomposition action are provided. The present invention relates to one or more kinds of Bifidobacterium bacteria selected from the group consisting of Bifidobacterium bifidum MCC1092 (NITE BP-02429), Bifidobacterium bifidum MCC1319 (NITE BP-02431), Bifidobacterium bifidum MCC1868 (NITE BP-02432), Bifidobacterium bifidum MCC1870 (NITE BP-02433), and Bifidobacterium longum subsp. longum MCC1110 (NITE BP-02430), as well as a composition for decomposing an opioid peptide and composition for decomposing a noncollagenous glycoprotein containing the Bifidobacterium bacteria as an active ingredient.

The present invention relates to a Bifidobacterium bifidum inducing regulatory T cells (Treg), a polysaccharide derived from Bifidobacterium bifidum, and a probiotic strain producing a polysaccharide and, more particularly, a polysaccharide containing β-1-6-glucan as an effective ingredient, a probiotic strain producing β-1-6-glucan, a food comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a therapeutic agent comprising the polysaccharide or strain as an effective ingredient for alleviation of immune disease or inflammatory disease, a method for preparing induced regulatory T cells (iTreg) by treatment with the polysaccharide or strain, and a cell therapy product for prevention or treatment of immune disease or inflammatory disease, comprising the induced regulatory T cells prepared by the method.

Disclosed are probiotic formulations comprising fortified avian eggs and avian egg products such as egg powder, and methods for producing the same substantially no meat containing growth media such as MRS. The formulations may be used to supplement food that include, but are not limited to, baby foods, milk, and pet foods. Effective amounts of the fortified egg formulations comprising at least about 10.sup.9 CFU/dosage of probiotics may be used to treat health issues that include, but are not limited to, irritable bowel syndrome. The probiotic formulation may comprise bacterial strains comprising at least one of L. casei, L. rhamnosus, B. breve, Bifidobacterium longum, L. acidophilus, L. plantarum, B. bifidum, L. fermentum, L. lactis, L. paracasei, and L. salivarius.

A maternal milk powder and a preparation method thereof. Every 100 g of the maternal milk powder comprises: (0.1-10)×10.sup.8 CFU of probiotics, 1-10 g of FOS; wherein, probiotics comprise Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium animalis, and Bifidobacterium bifidum with a CFU ratio of 20-40:20-40:1-10:10-20:10-20:1-10. The maternal milk powder can effectively inhibit the proliferation of harmful bacteria in the intestinal tract of pregnant women, promote the health of intestinal microecology, improve immunity, relieve postpartum depression, etc. by adding six kinds of safe, stable and efficient probiotics and FOS.

Disclosed are Bifidobacterium pseudocatenulatum C-RAPO (KCTC13986BP) and Bifidobacterium bifidum ATT (KCTC13474BP) strains that have the effects of inhibiting sialoadenitis, which is a symptom of the Sjogren's syndrome, and inhibiting a reduction in saliva flow rate. Based on this, these strains can be used for prevention or treatment of Sjogren's syndrome and can be developed into food, health food and pharmaceuticals.

A medicine, a food or a drink and feed which are effective for preventing and/or improving decline, occurring with age (senescence), in memory and learning ability are provided. A novel microorganism having the effect of preventing and/or improving decline, occurring with age (senescence,) in memory and learning ability is provided. More specifically, the microorganism is characterized by being a microorganism belonging to Lactobacillus, Bifidobacterium, Streptococcus, Leuconostoc or Pediococcus, more specifically a microorganism belonging to any of Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus gallinarum, Lactobacillus johnsonii, Lactobacillus delbrueckii subsp. delbrueckii, Bifidobacterium catenulatum, Bifidobacterium pseudolongum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Streptococcus thermophiles, Leuconostoc mesenteroides subsp. dextranicum, Leuconostoc lactis, Pediococcus acidilactici and Pediococcus pentosaceus.

This document provides dietary supplement compositions. For example, multi-supplement compositions having combinations of dietary supplement formulations useful for human or animal consumption are provided.

A composition and method for use of a dietary supplement for promoting gastrointestinal health including effective amounts of probiotics, digestive enzymes, prebiotics, a dried, non-viable yeast, protein, B vitamins, and flavoring agent. The multi-strain of probiotics may be viable and dried bacteria like Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium animalis subsp. Lactis and Streptococcus thermophilus. The multistrain and multispecies probiotics may show synergistic effects. Digestive enzymes can be protease, lactase, cellulose, and/or pancreatin. The prebiotics may be inulin and other dietary fiber. The yeast may be Brewer's or Baker's yeast. The protein may be whey or soy or rice protein concentrates. The B vitamins may be Pantothenic Acid, Thiamine, Riboflavin, Niacinamide, Pyridoxine, Cyanocobalamin, Folic Acid and Biotin. The flavoring agent may be natural vanilla.